TOG Review (RCOG Journal)

MRCOG Part 2

Gynaecological Problems

Hormone replacement therapy and breast disease

Key Statistics

  • 1 in 9 — UK lifetime breast cancer risk
  • RR 1.35 — Combined HRT >5yr use (1997 re-analysis)
  • 4–5× — Risk with biopsy-proven atypia

Don't-miss facts

  1. Progestogen – not estrogen – drives the added breast cancer risk with HRT

  2. Unopposed estrogen ≤5yr: no increase in diagnosis risk (CEE and estradiol valerate similar, any route)

  3. Combined HRT: risk emerges after 3 years (WHI); RR 1.35 for >5yr use (1997 re-analysis)

  4. LNG-IUS is NOT risk-free as HRT progestogen component – case-control data show increased risk

  5. Only biopsy-proven atypia raises risk from benign breast disease: 4–5×

  6. BRCA1 lifetime risk 44–78%; BRCA2 31–56%; familial disease = ~10% of cases; HRT does not add to this baseline risk

  7. HABITS, Stockholm, national UK trial, LIBERATE all closed prematurely – HABITS & LIBERATE (tibolone, ER+ve) showed increased recurrence

  8. No robust evidence HRT worsens breast cancer survival overall – MWS 22% mortality increase is the outlier and methodologically flawed

Risk at a glance

Unopposed estrogen ≤5yr: no significant ↑risk Combined HRT >3yr / LNG-IUS / synthetic progestogens: ↑risk

Abbreviation Key

  • HRT — hormone replacement therapy
  • BRCA1/2 — breast cancer susceptibility gene 1/2
  • WHI — Women’s Health Initiative
  • HABITS — Hormonal replacement therapy After Breast cancer—Is IT Safe? trial
  • MWS — Million Women Study
  • LIBERATE — Livial Intervention following Breast cancer: Efficacy,
  • CEE — conjugated equine estrogen Recurrence, And Tolerability study
  • LNG-IUS — levonorgestrel-releasing intrauterine system
  • RR — relative risk
  • ER+ve/ER−ve — estrogen receptor-positive/negative
  • EMBRACE — Epidemiological Study of Familial Breast Cancer
  • NICE — National Institute for Health and Clinical Excellence (Cancer Research UK)

Source: Marsden J. Hormone replacement therapy and breast disease. The Obstetrician & Gynaecologist 2010;12:155–163. doi:10.1576/toag.12.3.155.27597

MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).

Included with a Pass Package

  • Audio overview of this guideline
  • Practice questions drawn from it
  • AI tutor answers grounded in its text
  • Your own annotations
Start free